177 related articles for article (PubMed ID: 19428549)
1. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma.
Stahl S; Sacher T; Bechtold A; Protzer U; Ganss R; Hämmerling GJ; Arnold B; Garbi N
Immunol Lett; 2009 Mar; 123(1):31-7. PubMed ID: 19428549
[TBL] [Abstract][Full Text] [Related]
2. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance.
Buschow C; Charo J; Anders K; Loddenkemper C; Jukica A; Alsamah W; Perez C; Willimsky G; Blankenstein T
J Immunol; 2010 Mar; 184(6):2930-8. PubMed ID: 20142365
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
5. [Immunization with dendritic cells infected with human AFP adenovirus vector effectively elicits immunity against mouse hepatocellular carcinomas].
Tan XH; Zhu Q; Liu C; Liu XL; Shao XT; Wei B
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):13-6. PubMed ID: 16737612
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
Toes RE; van der Voort EI; Schoenberger SP; Drijfhout JW; van Bloois L; Storm G; Kast WM; Offringa R; Melief CJ
J Immunol; 1998 May; 160(9):4449-56. PubMed ID: 9574550
[TBL] [Abstract][Full Text] [Related]
7. The immune response to sporadic colorectal cancer in a novel mouse model.
Czéh M; Loddenkemper C; Shalapour S; Schön C; Robine S; Goldscheid E; Stein H; Schüler T; Willimsky G; Blankenstein T
Oncogene; 2010 Dec; 29(50):6591-602. PubMed ID: 20818425
[TBL] [Abstract][Full Text] [Related]
8. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
[TBL] [Abstract][Full Text] [Related]
9. Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model.
Romieu R; Baratin M; Kayibanda M; Lacabanne V; Ziol M; Guillet JG; Viguier M
J Immunol; 1998 Nov; 161(10):5133-7. PubMed ID: 9820481
[TBL] [Abstract][Full Text] [Related]
10. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
14. [Effect of tumor antigen specific CTL induced by dendritic cells on a model of human hepatocellular carcinoma in nude mice (LCI-D20)].
Chen GL; Hu HD; Ma YJ; Li YG; Xue Q; Chen M; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2006 Jun; 14(6):431-4. PubMed ID: 16792867
[TBL] [Abstract][Full Text] [Related]
15. [Adenovirus vector encoding human KDR elicits immunity against hepatocellular carcinomas in mice].
Tan XH; Wu B; Liu B; Liu XL; Wang YC
Zhonghua Gan Zang Bing Za Zhi; 2008 Apr; 16(4):289-93. PubMed ID: 18423153
[TBL] [Abstract][Full Text] [Related]
16. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes.
Grossmann ME; Davila T; Celis T
J Immunother; 2001; 24(3):237-41. PubMed ID: 11394501
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of SV40 induced tumours in mice: a model for vaccine development.
Bright RK; Shearer MH; Pass HI; Kennedy RC
Dev Biol Stand; 1998; 94():341-53. PubMed ID: 9776255
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
20. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
